Articles

Find an Article

Filter articles

Applied Filters

Showing 281 to 290 of 314 results

Teaching old drugs new tricks

US30-09-2013

Developing new drugs is time-consuming and expensive. DelMar Pharma researches old drugs and establishes new IP around them to streamline the process. LSIPR spoke to chief executive Jeffrey Bacha about the company’s approach.

Spiral Genetics: clarifying the gene pool

US31-08-2013

In 1990, the Human Genome Project began its quest to identify every gene in the human genome. Now, Spiral Genetics can sequence a human genome in three hours. LSIPR spoke to Spiral Genetics’ chief executive Adina Mangubat to find out how the company protects its IP.

Keeping secrets: protecting the smallpox vaccine

31-07-2013

Danish firm Bavarian Nordic has a portfolio of patents for vaccines and cancer treatments, but likes to keep some of its cards close to its chest, as LSIPR finds out.

Current barriers to biotech in Brazil

Brazil31-07-2013Gabriel Di Blasi

Gabriel Di Blasi outlines the existing impediments to developing new biotechnology products in Brazil, and considers recent efforts to improve the situation.

A rare opportunity: aTyr Pharma and orphan drugs

US28-06-2013

As support for the study of rare diseases picks up, how does a good IP strategy bring orphan drugs to market? LSIPR spoke to aTyr Pharma’s chief executive John Mendlein to find out.

Myriad: picking up the pieces

US28-06-2013Janis Fraser

The US Supreme Court in a landmark decision held that a DNA molecule is potentially eligible for patenting in the US if its sequence does not occur in nature, but is not patent-eligible if its sequence is identical to a naturally occurring DNA sequence.

Obviousness of DNA fragments in the post-Kubin era

US30-04-2013James Monroe and Lawrence Ilag

James Monroe and Lawrence Ilag of Finnegan, Henderson, Farabow, Garrett & Dunner LLP analyse the impact of the US Court of Appeals for the Federal Circuit’s decision In re Kubin.

A global approach: Novo Nordisk's IP strategy

EU30-04-2013

While the global trend is towards a “more hostile IP environment” for pharmaceutical companies, Danish healthcare giant Novo Nordisk A/S continues to perform. LSIPR talks to Lars Kellberg, corporate vice president, about how it meets the challenges.

Patent term restoration and adjustment in Mexico: a TPP possibility?

Australia, Brunei, Canada, Chile, Malaysia, Mexico, Peru, Singapore, US, Vietnam30-04-2013Jose R. Trigueros

Patent term restoration has been adopted by several jurisdictions, with varying success. Mexico faces several issues with sanitary authorisations and patent examination, so patent term restoration would be a viable remedy for patent holders. The TPP might enable this.

Considerations for biopharma under a first-inventor-to-file regime

01-04-2013Kenley Hoover

The sweeping reform brought about by the AIA includes the FITF patent system, which places a premium on maintaining confidentiality, and speed and efficiency in filing patent applications while juggling the uncertainties and nuances of this new system.

Showing 281 to 290 of 314 results

LSIPR